Every Form 4 that Alterity Therapeutics Ltd (ATHE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ATHE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ATHE filings page.
ALTERITY THERAPEUTICS LTD (ATHE) director Peter Ashley Marks reported related transactions on August 31, 2026 through Lampam Pty Ltd. An entity associated with him bought 47,620 ordinary shares at $0.50 per share, bringing its indirect holdings to 191,340 ordinary shares, and disposed of 47,620 listed options with a $0.50 exercise price expiring August 31, 2026.
ALTERITY THERAPEUTICS LTD (ATHE) reported that Chief Executive Officer and director David Allen Stamler recorded a disposition involving derivative securities tied to the company’s ordinary shares. On August 31, 2026, he reported a transaction in 47,620 listed options expiring August 31, 2026 at a reported price of $0.50 per option, with 47,620 underlying ordinary shares. Following the transaction, this listed option position is shown as 0 derivative securities held directly.
ALTERITY THERAPEUTICS LTD director Julian Michael Babarczy, through Vaucluse Investment Holdings Pty Ltd <Jigsaw Investment A/C>, received a grant of unlisted options on June 15, 2026. The award covers 2,000,000 options, each exercisable into one ordinary share at an exercise price of 1.0000 per share, expiring on June 15, 2031. This is a compensation-related acquisition of derivative securities, not an open-market share purchase or sale, and leaves 2,000,000 options held indirectly following the transaction.
ALTERITY THERAPEUTICS LTD director Lawrence Bernard Gozlan, through Montoya Pty Ltd <Buttercup A/C>, received a grant of derivative securities. The award consists of 1,000,000 listed options, each exercisable into one ordinary share at an exercise price of $1.0000 per share.
The options were granted on 15 June 2026 and expire on 15 June 2031. Following this grant, the indirect holdings reported in this listed option position total 1,000,000 options.